The personalised medicine company Progenika is pursuing its international expansion and has recently set up its innovative technology in Kuwait. The National Blood Bank of Kuwait, the most important blood bank in the country, is now equipped with cutting edge technology to ensure compatibility between donor and receiver in blood transfusions.

Progenika, the first personalized medicine company to move into Kuwait, has installed its BLOODchip blood group and platelet genotyping platform through its sales office in the United Arab Emirates. This in-house technology is already being used in the main blood banks in Spain, Europe and the Arab countries. This is the latest technology applied to blood groups through the analysis of the DNA of 9 different blood groups.

The DNA extracted from one blood sample is used to analyse 128 mutations permitting the identification of more than 60 phenotypes, the totality of characteristics in one person, and 12 platelet antigens related with immune response. This information enables the health specialist to select the ideal donor and offer patients maximum safety during blood transfusions.

According to Science, Progenika is the foremost company for the detection of risks in blood transfusions.

This move continues Progenika’s expansion in the Middle East, which began in 2008 with the introduction of the BLOODchip into the United Emirates, and makes it the personalized medicine company of reference in this part of the world.